Propeller Health Platform Wins Expanded FDA Indication
Propeller Health has won expanded FDA 510(k) clearance of its digital health platform for use with medications incorporating GlaxoSmithKline’s Diskus dry powder inhaler for asthma and chronic obstructive pulmonary disease.
The move follows the Propeller platform’s 510(k) clearance in March for use with medications associated with Boehringer Ingelheim’s Respimat inhaler for chronic obstructive pulmonary disease. The device was FDA-approved in 2012.
The product relies on sensor technology to monitor the use of inhaled rescue and controller medication in asthma and COPD patients, analyze trends and report feedback, the Madison, Wisc., devicemaker said Wednesday.
In addition, it has been shown to predict oncoming exacerbations, increase patient adherence and reduce the frequency of symptoms. — Jason Scott